IMMUNOME INC (IMNM) Fundamental Analysis & Valuation

NASDAQ:IMNM • US45257U1088

Current stock price

23.39 USD
-0.39 (-1.64%)
Last:

This IMNM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMNM Profitability Analysis

1.1 Basic Checks

  • In the past year IMNM has reported negative net income.
  • In the past year IMNM has reported a negative cash flow from operations.
  • IMNM had negative earnings in each of the past 5 years.
  • IMNM had a negative operating cash flow in each of the past 5 years.
IMNM Yearly Net Income VS EBIT VS OCF VS FCFIMNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • IMNM has a Return On Assets of -31.09%. This is in the better half of the industry: IMNM outperforms 63.57% of its industry peers.
  • The Return On Equity of IMNM (-33.48%) is better than 73.06% of its industry peers.
Industry RankSector Rank
ROA -31.09%
ROE -33.48%
ROIC N/A
ROA(3y)-74.98%
ROA(5y)-84.72%
ROE(3y)-94.76%
ROE(5y)-112.18%
ROIC(3y)N/A
ROIC(5y)N/A
IMNM Yearly ROA, ROE, ROICIMNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • IMNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNM Yearly Profit, Operating, Gross MarginsIMNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IMNM Health Analysis

2.1 Basic Checks

  • IMNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMNM has been increased compared to 1 year ago.
  • The number of shares outstanding for IMNM has been increased compared to 5 years ago.
  • IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMNM Yearly Shares OutstandingIMNM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
IMNM Yearly Total Debt VS Total AssetsIMNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 31.61 indicates that IMNM is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 31.61, IMNM belongs to the top of the industry, outperforming 92.44% of the companies in the same industry.
  • IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 31.61
ROIC/WACCN/A
WACC9.55%
IMNM Yearly LT Debt VS Equity VS FCFIMNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • IMNM has a Current Ratio of 14.69. This indicates that IMNM is financially healthy and has no problem in meeting its short term obligations.
  • IMNM has a better Current ratio (14.69) than 91.28% of its industry peers.
  • IMNM has a Quick Ratio of 14.69. This indicates that IMNM is financially healthy and has no problem in meeting its short term obligations.
  • IMNM has a better Quick ratio (14.69) than 91.28% of its industry peers.
Industry RankSector Rank
Current Ratio 14.69
Quick Ratio 14.69
IMNM Yearly Current Assets VS Current LiabilitesIMNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IMNM Growth Analysis

3.1 Past

  • IMNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.00%, which is quite impressive.
  • IMNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.23%.
EPS 1Y (TTM)53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
Revenue 1Y (TTM)-23.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • IMNM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.79% yearly.
  • IMNM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 141.10% yearly.
EPS Next Y-3.29%
EPS Next 2Y2.14%
EPS Next 3Y14.34%
EPS Next 5Y23.79%
Revenue Next Year-10.96%
Revenue Next 2Y230.58%
Revenue Next 3Y216.45%
Revenue Next 5Y141.1%

3.3 Evolution

IMNM Yearly Revenue VS EstimatesIMNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
IMNM Yearly EPS VS EstimatesIMNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMNM Valuation Analysis

4.1 Price/Earnings Ratio

  • IMNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IMNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNM Price Earnings VS Forward Price EarningsIMNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNM Per share dataIMNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • IMNM's earnings are expected to grow with 14.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.14%
EPS Next 3Y14.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMNM Dividend Analysis

5.1 Amount

  • No dividends for IMNM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMNM Fundamentals: All Metrics, Ratios and Statistics

IMMUNOME INC

NASDAQ:IMNM (4/23/2026, 10:44:10 AM)

23.39

-0.39 (-1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-07
Inst Owners102.62%
Inst Owner Change0.07%
Ins Owners1.15%
Ins Owner Change-5.11%
Market Cap2.65B
Revenue(TTM)6.94M
Net Income(TTM)-212.39M
Analysts85
Price Target35.96 (53.74%)
Short Float %18.11%
Short Ratio14.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.37%
Min EPS beat(2)-23.77%
Max EPS beat(2)-10.97%
EPS beat(4)2
Avg EPS beat(4)-0.57%
Min EPS beat(4)-23.77%
Max EPS beat(4)25.15%
EPS beat(8)2
Avg EPS beat(8)-57.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)2
Avg Revenue beat(4)288.78%
Min Revenue beat(4)-100%
Max Revenue beat(4)904.04%
Revenue beat(8)3
Avg Revenue beat(8)137.6%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.95%
PT rev (3m)2.31%
EPS NQ rev (1m)-0.27%
EPS NQ rev (3m)6.11%
EPS NY rev (1m)6.56%
EPS NY rev (3m)6.87%
Revenue NQ rev (1m)-11.11%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 381.23
P/FCF N/A
P/OCF N/A
P/B 4.17
P/tB 4.17
EV/EBITDA N/A
EPS(TTM)-2.43
EYN/A
EPS(NY)-2.51
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0.06
BVpS5.61
TBVpS5.61
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -31.09%
ROE -33.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.98%
ROA(5y)-84.72%
ROE(3y)-94.76%
ROE(5y)-112.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 646.03%
Cap/Sales 229.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.69
Quick Ratio 14.69
Altman-Z 31.61
F-Score5
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)1414.18%
Cap/Depr(5y)862.52%
Cap/Sales(3y)275.76%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
EPS Next Y-3.29%
EPS Next 2Y2.14%
EPS Next 3Y14.34%
EPS Next 5Y23.79%
Revenue 1Y (TTM)-23.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-10.96%
Revenue Next 2Y230.58%
Revenue Next 3Y216.45%
Revenue Next 5Y141.1%
EBIT growth 1Y-39.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.95%
EBIT Next 3Y14.24%
EBIT Next 5YN/A
FCF growth 1Y-25.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.32%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOME INC / IMNM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IMMUNOME INC (IMNM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMNM.


What is the valuation status for IMNM stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNOME INC (IMNM). This can be considered as Overvalued.


How profitable is IMMUNOME INC (IMNM) stock?

IMMUNOME INC (IMNM) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for IMNM stock?

The Earnings per Share (EPS) of IMMUNOME INC (IMNM) is expected to decline by -3.29% in the next year.